AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs).

NP-12 TFA displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions .
NP-12 TFA rescues the proliferation in the mouse splenocyte assay system with average EC₅₀ values of 17 nM and 16.6 nM against rmPD-L1 and rmPD-L2 respectively .
NP-12 TFA is also able to significantly rescue recombinant human PD-L1 and PD-L2 mediated inhibition of in vitro human PBMC proliferation, with average EC₅₀ values of 63.3 nM and 44.1 nM against PD-L1 and PD-L2 respectively .

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Sasikumar PG, et al. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Mol Cancer Ther. 2019 Jun;18(6):1081-1091.  [Content Brief]